MedDataX Logo

CT Perfusion Changes in GI Cancer During Adenosine Vasodilation Test

NCT ID: NCT02074124

Last Updated: 2014-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

15 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to investigate changes in abdominal tissue perfusion during adenosine vasodilation. Our hypotheses were that CT perfusion measurements are altered by changes in the circulatory system mediated by adenosine, and a more differentiated assessment of the circulatory capacity of abdominal tumours could be achieved by sequential rest and adenosine vasodilation CT perfusion measurements.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Esophageal Cancer Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Adenosine Vasodilation test

Group scanned with CT perfusion during adenosine vasodilation test.

No interventions assigned to this group

Reference group

Group scanned twice without adenosine vasodilation test for a reference. No randomization.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Tumour larger than 1.5 cm on diagnostic CT
* Normal serum creatinine
* Age above 18
* Informed written and oral consent.

Exclusion Criteria

* Contrast allergy or contrast induced nephropathy
* BMI \> 40
* Asthma or Chronic Obstructive Lung Disease
* Heart failure (NYHA III+)
* Heart conduction disorder
* Atrial fibrillation
* 2nd/3rd Heart block
* Long QT syndrome
* Wolf Parkinson White Syndrome
* Moderate / severe aortic stenosis
* Haemodynamic contraindications for adenosine, systolic pressure below 90
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Copenhagen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Martin Lundsgaard Hansen

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Martin L Hansen, MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Rigshospitalet

Copenhagen, , Denmark

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Denmark

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

H-3-2012-067

Identifier Type: OTHER

Identifier Source: secondary_id

H-3-2012-067

Identifier Type: -

Identifier Source: org_study_id